Merilog (insulin aspart-szjj) Patient Assistance Program
Don’t let the high cost of brand rapid-acting insulin disrupt your diabetes treatment. We help eligible patients access Merilog (insulin aspart-szjj — biosimilar to NovoLog/Fiasp) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Merilog (insulin aspart-szjj) is FDA-approved as a biosimilar (interchangeable) to insulin aspart (NovoLog/Fiasp) — a rapid-acting mealtime insulin for treatment of diabetes in adults and pediatric patients. The first insulin aspart biosimilar. Same amino acid sequence as reference NovoLog with equivalent efficacy and safety.
- Without assistance, Merilog costs commonly run approximately $50–$150 per vial or pen — significantly less than brand NovoLog.
- Through AffordMyPrescriptions, qualifying patients can access Merilog for a flat $69.95 per month.
- Reference product: NovoLog (insulin aspart — brand) and Fiasp (faster-acting aspart — brand). Other rapid-acting insulins: Humalog (lispro — brand and biosimilars Admelog, Lyumjev), Apidra (glulisine — brand). Under IRA, Medicare Part D insulin is capped at $35/month copay. Various state insulin price caps. Manufacturer copay programs may cap insulin cost at $35/month for uninsured or underinsured patients (Novo Nordisk, Lilly, Sanofi voluntary caps). Diabetes management requires basal + bolus insulin for many T1DM/T2DM patients.
What is Merilog Prescription Assistance Program?
The Merilog Patient Assistance Program helps eligible patients access this insulin aspart biosimilar at little or no cost when meeting income, insurance, and clinical criteria. The IRA Medicare Part D insulin cap ($35/month) and voluntary manufacturer insulin caps may apply.
At AffordMyPrescriptions, our Patient Advocates handle the entire Merilog PAP enrollment for a flat $69.95 per month — so you never face a gap in Merilog diabetes therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Merilog enrollment — so you never face a gap in your diabetes insulin therapy.
Pharmacy Price Comparison
- Without assistance, insulin costs can be high — biosimilars are significantly cheaper. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| IRA Medicare Part D cap | $35/mo | IRA Medicare cap |
| Walgreens | ~$140/vial | Save substantially |
| CVS Pharmacy | ~$150/vial | Save substantially |
| Walmart | ~$80/vial | Save substantially |
| Costco | ~$50/vial | Save substantially |
| NovoLog brand | ~$300/vial | Brand reference product |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Merilog — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Merilog Prescription Program?
The Merilog Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. The IRA Medicare Part D insulin cap ($35/month) is a major resource for Medicare beneficiaries. Voluntary manufacturer insulin caps ($35/month) are available for many uninsured/underinsured. Biosimilar insulins offer significant cost savings vs brand.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Merilog assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Merilog is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Merilog:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $50–$150 biosimilar / $300 brand per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Merilog assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Merilog Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Merilog:
Merilog is the first FDA-approved insulin aspart biosimilar — a biosimilar to brand NovoLog. Same amino acid sequence, equivalent efficacy and safety, at significantly lower cost. A rapid-acting mealtime (bolus) insulin for diabetes management.
How It Works:
Diabetes management involves matching insulin dosing to physiologic insulin needs. Basal insulin (long-acting) covers overnight and between-meal glucose control; bolus insulin (rapid-acting) covers meals and hyperglycemia correction. Rapid-acting insulin analogs (aspart, lispro, glulisine) have faster onset and shorter duration than regular human insulin — better mimicking physiologic mealtime insulin. Insulin aspart (NovoLog reference product; Merilog biosimilar) has a single amino acid substitution vs human insulin — increasing the dissociation rate for rapid absorption. Onset ~15 minutes, peak ~1–3 hours, duration ~3–5 hours. Take at meal time. Merilog is a biosimilar — same amino acid sequence, equivalent efficacy and safety per FDA. Interchangeable designation allows substitution at pharmacy per state law.
Form and Use:
Merilog SC injection for meals and correction (or via pump). Vials and pens available. Dose based on carbohydrate counting and glucose levels — individualized. Diabetes education for proper insulin administration technique.
Generic Availability:
Merilog is a biosimilar to NovoLog (insulin aspart). Similar insulin biosimilars: Semglee (insulin glargine-yfgn — biosimilar to Lantus), Rezvoglar (biosimilar to Lantus), Basaglar (Lantus follow-on), Admelog (insulin lispro biosimilar to Humalog), Lyumjev (faster-acting lispro — brand). Other rapid-acting insulins: Humalog (lispro — brand), Apidra (glulisine — brand), Fiasp (faster-acting aspart — brand). Long-acting insulins: Lantus (glargine — brand and biosimilars), Toujeo (glargine U-300 — brand), Tresiba (degludec — brand), Basaglar, Semglee, Rezvoglar. Under IRA Medicare Part D insulin is capped at $35/month; voluntary manufacturer caps also exist. American Diabetes Association resources.
Warnings:
Hypoglycemia (the most common insulin adverse effect; educate patients on prevention and treatment — sugar, glucose tablets, glucagon rescue), severe hypoglycemia (unconsciousness, seizure — requires glucagon or emergency care), hypokalemia (insulin drives potassium intracellularly), hypersensitivity reactions (rare — including anaphylaxis), lipodystrophy at injection sites (rotate sites), weight gain (chronic insulin therapy), embryo-fetal considerations (insulin is generally required in diabetic pregnancy — safe with careful glucose monitoring), fluid retention with concomitant thiazolidinediones. Other: injection site reactions. Continuous glucose monitoring or frequent testing is important. Diabetes education is essential.
FAQ (Frequently Asked Questions)
How much does Merilog cost without insurance?
$50–$150 per vial or pen at pharmacies — significantly cheaper than brand NovoLog (~$300/vial). Under IRA Medicare Part D, insulin is capped at $35/month copay. Voluntary manufacturer insulin caps ($35/month) are available for many uninsured/underinsured.
How is Merilog different from NovoLog?
Merilog is a biosimilar to NovoLog (insulin aspart) — same amino acid sequence, equivalent efficacy and safety per FDA. Merilog is designated interchangeable — it can be substituted at the pharmacy per state law without prescriber re-authorization in most states. Significant cost savings, same clinical use.
How is Merilog different from Fiasp?
Both are insulin aspart products from the same reference. Fiasp is a faster-acting formulation of insulin aspart (contains niacinamide for faster absorption) — brand only. Merilog is a biosimilar to standard NovoLog aspart. Similar clinical use with slight timing differences.
How is Merilog different from Humalog (insulin lispro)?
Both are rapid-acting insulin analogs for mealtime bolus dosing, with similar onset, peak, and duration — often interchangeable in practice. Choice depends on brand/biosimilar availability, insurance coverage, and prescriber preference. Insulin lispro biosimilars (Admelog) and Humalog brand are also available.
What are Merilog side effects?
Same as brand NovoLog: hypoglycemia (most common — educate on prevention and treatment; use continuous glucose monitor or frequent testing), hypokalemia, hypersensitivity (rare), lipodystrophy at injection sites (rotate), weight gain, injection site reactions. Diabetes education is essential.
Take Control of Your Medication Costs
Affordable insulin is essential for diabetes management. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.